News

Eyenovia Announces Co-Branded Validator with Kinetiq 

Kinetiq x Hyperion provides a premier liquid staking solution for institutional HYPE holdersLAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE)…

6 months ago

Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions

Comprehensive analysis confirms safety and strong accuracy of Glucotrack's innovative blood-based continuous glucose monitoring technology, with MARD of 7.7%RUTHERFORD, N.J.…

6 months ago

OneMedNet CEO Aaron Green Issues Letter to Shareholders Highlighting Strategic Progress

MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World…

6 months ago

SeaStar Medical Reports Update on Nasdaq Listing Status

DENVER, June 25, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming…

6 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…

6 months ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Initial computational analysis demonstrated that Evaxion’s AI-Immunology™ platform can identify novel vaccine targets to combat Group A Streptococcus (GAS)New vaccine…

6 months ago

Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors

Former Pfizer Chief Scientific Officer brings decades of drug development and strategic leadership experience to Arbor’s BoardCAMBRIDGE, Mass., June 25,…

6 months ago

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of…

6 months ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final…

6 months ago

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck…

6 months ago